Beijing Tiantan Biological Products Corporation Limited
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Tiantan Biological Products Co., Ltd. (referred to as "Tiantan Biological", stock code: 600161. SH) was listed in 1998, and its main business is the research and development, manufacturing, sales, and consulting services of blood products. After two major asset restructurings in 2010 and 2017, Tiantan Biotechnology has become a specialized operating company for blood products of China Biotechnology Co., Ltd. Tiantan Biotechnology has six blood product production enterprises, including Chengdu Rongsheng, Lanzhou Blood, Shanghai Blood, Wuhan Blood, Guizhou Blood, and Xi'an Blood. At present, there are 102 single plasma collection stations (including sub stations) in 16 provinces and autonomous regions across the country, including 70 operating single plasma collection stations (including sub stations) and 32 planned single plasma collection stations. The collection scale of healthy human plasma for blood product production is in a leading position in China. In 1966, Tiantan Biotechnology took the lead in implementing the industrialization of low-temperature ethanol process for preparing blood products in China. At present, the production scale of blood products is in a leading position in China, with 72 product identification numbers for the three major categories of blood albumin, human immunoglobulin, and human coagulation factor. Tiantan Biotechnology has a group of technical personnel who have been engaged in the research and development of plasma protein products for many years, with strong technical strength. The blood product enterprises under the Tiantan umbrella have held multiple firsts in the domestic blood product industry, launching products such as human serum albumin, intravenous immunoglobulin (pH4), and tetanus immunoglobulin for the first time in China. They have also taken the lead in introducing plasma protein filtration and separation processes, and established a research and development platform for plasma protein products, virus inactivation process technology validation, and recombinant products. At present, the variety and quantity of Tiantan Biological Products are among the top in China, and the blood products produced have a large market share in the domestic market, with comprehensive advantages in quality, scale, and brand. In addition, Chengdu Rongsheng, a subsidiary of Tiantan Biotechnology, has independently developed recombinant human coagulation factor VIII for injection, which has received a clinical trial approval issued by the State Food and Drug Administration. The research and development of recombinant blood products has achieved zero breakthroughs. Tiantan Biotechnology is committed to providing society with more varieties, quantities, and high-quality blood products, striving to become a leading and world-class blood product enterprise in China. |
| Headquarter | Beijing |
| Establish Date | 6/8/1998 |
| Listed Code | 600161.SH |
| Listed Date | 6/16/1998 |
| Chairman | Yang Huichuan. |
| CEO | Fu Daoxing. |
| Website | www.TiantanBio.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
